Pharmaceuticals company Suven Life Sciences announced Q4FY24 & FY24 results:<br><br>Financial Highlights:<br><br>Suven Life Sciences reported a revenue of Rs 66.7 million in Q4FY24, showing a decline compared to the previous quarter's revenue of Rs 85.2 million.<br><br>The company experienced a net loss after tax of Rs 265.4 million in Q4FY24, and a cumulative annual loss of Rs 1,050.8 million for the year FY24.<br><br>Expenses Breakdown:<br><br>R&D; and Operational expenses accounted for a significant portion of the total expenses, posting Rs 326.7 million for the quarter and Rs 1,397 million for the year.<br><br>Depreciation and Amortisation costs were recorded at Rs 15.1 million for the quarter, while Finance costs were relatively low at Rs 0.3 million.<br><br>Exceptional Items: <br><br>An exceptional item included in the financials reflects an insurance claim received by the company, amounting to Rs 10.0 million.<br><br>Comprehensive Income: <br><br>The total comprehensive income for the quarter reflects a loss of Rs 267.4 million after factoring in other comprehensive income, which was a loss of Rs 2.0 million.<br><br>Stock and Earnings per Share:<br><br>The paid-up equity capital stood constant at Rs 218.1 million for the reported periods, while the Earnings Per Share (EPS) showed a loss of Rs 1.2 for the quarter and a loss of Rs 4.8 for the full year. <br><br>Result PDF